Mechanistically, the observed synergy between losartan and vitamin D is attributed to complementary regulation of RAS: losartan blocked AT1R to suppress the pro-tumor axis, while vitamin D enhances ACE2 levels, thereby promoting the anti-tumor ACE2/Ang(1-7)/MasR axis [119]. This evidence concerns the gene MAS1L and neoplasm.